Skip to main content
OpenTrials
Completed

NCT Number: NCT01820949

Safety and Effectiveness of a Patient Blood Management (PBM) Program in Surgical Patients

This study will evaluate clinical outcome after the step-wise implementation of a Patient Blood Management (PBM) Program in surgical patients at 4 hospitals.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital Bonn, Bonn, Germany

Loading trial locations.

About this study

A PBM program will be implemented stepwise in four University Hospitals, with the intention to optimize preoperative hemoglobin concentration of patients and to standardize transfusion practice within hemotherapy. The PBM program includes 1) an algorithm with the aim to correct preoperative anemia in elective surgery, 2) a strict indication for the transfusion of red blood cells defined by the "Cross-sectional Guidelines for Therapy with Blood Components and Plasma Derivatives" for all surgical patients, and 3) a perioperative checklist for different blood-sparing techniques (e.g. cell-saver, normothermia, reduced blood samples, point-of-care diagnostics for bedside coagulation management).

Primary endpoint: Safety of the use of PBM program will be determined by comparability of the composite outcome (in-hospital myocardial infarction, stroke, acute renal failure, death of any cause, pneumonia and sepsis until discharge from hospital) between patients treated after implementation and patients treated before implementation (control cohort) of the PBM program.

The primary composite endpoint defined as described above will be registered electronically by analysis of Diagnosis Related Groups (DRG) codes. The frequency of these events will be compared between PBM and control cohort stratified by center with a one-sided Mantel-Haenszel test in a non-inferiority setting with significance level of α=2.5% and a non-inferiority margin of 1% for the incidence of the composite endpoint.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All non- ambulant, surgical, anesthetized patients (≥18 years)
  • General Surgery, Cardiac Surgery, Thoracic Surgery, Trauma Surgery, Vascular Surgery, Urology, Gynecology, Otolaryngology, Neurosurgery, Crania-Maxillofacial Surgery

Exclusion criteria

  • ambulant and all non-surgical anesthetic procedures
  • Surgery in the field of Dermatology or Ophthalmology

Treatment and study plan

Primary outcomes

  1. Myocardial infarction, stroke, acute renal failure, death of any cause, pneumonia and sepsisComposite outcome

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks

    Composite endpoint defined as in-hospital myocardial infarction, stroke, acute renal failure, death of any cause, pneumonia and sepsis until discharge from hospital

Secondary outcomes

  1. Length of stay on the intensive care unit

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks

  2. Total hospital stay

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks

  3. Total number of red blood cell transfusions during hospital stay

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks

  4. Consumption of coagulation factors

    Time frame: Participants will be followed for the duration of hospital stay, an expected average of 2 weeks

Sponsors and collaborators

Lead sponsor

Johann Wolfgang Goethe University Hospital

Other

Collaborators

  • B. Braun Melsungen AG
  • CSL Behring
  • Fresenius Kabi
  • University Hospital Muenster
  • University Hospital Schleswig-Holstein
  • University Hospital, Bonn
  • Vifor Pharma

Registry information

Acronym: PBM

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Mar 29, 2013
Registry last updated
Sep 7, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.